Faculty Perspectives Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine

Economics & Value

First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML

Real-World Healthcare Utilization and Costs Support Broader Use of CAR T-Cell Therapy

Value-Based Care Management Medicare Program Changes for 2020 and Beyond

Joseph S. Bailes, MD, Gena Cook

View More Articles

Personalized Medicine

Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive

Liquid Biopsies on the Horizon for Children With Solid Cancers

Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma

View More Articles

Value in Oncology

NCCN Panel Debates Cancer Care in Value-Based Healthcare Models

FDA Implements New Steps to Encourage Generic Drug Competition, Expand Patients’ Access to Inexpensive Medicines

Eileen Koutnik-Fotopoulos

Rapid Adoption of Oncology Drugs Improves Survival

View More Articles

FDA Approvals, News & Updates

Fruzaqla FDA Approved for Relapsed Metastatic Colorectal Cancer

FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Metastatic or Recurrent Nasopharyngeal Carcinoma

Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of GEJ Adenocarcinoma

View More Articles

Emerging Therapies

Zanidatamab Demonstrates Efficacy in Refractory HER2-Amplified Biliary Tract Cancer

Investigational mRNA-Based Vaccine May Offer New Hope for Patients With High-Risk Melanoma

First-Line Mosunetuzumab Safe and Effective in Older Patients with Diffuse Large B-Cell Lymphoma

View More Articles

Immunotherapy

Immunotherapy After Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer

Sharon Reynolds

Personalized Vaccine plus Immune Checkpoint Inhibitor a Promising Approach to Cancer

FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer

Yvette Florio Lane

View More Articles

Faculty Perspectives Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine

Faculty Perspectives Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine

For this supplement, expert faculty provided detailed perspectives based on their extensive experience in the management of non–small cell lung cancer (NSCLC), focusing on the incorporation and importance of biomarker testing in precision medicine for improved patient care.